Parexel appoints Jim Anthony as CCO and President, Parexel Biotech
Anthony brings more than 25 years of pharmaceutical development and CRO experience to his expanded role
Anthony brings more than 25 years of pharmaceutical development and CRO experience to his expanded role
KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone
Vivo Bio Tech will have end-to-end responsibility for conducting the full spectrum of pre-clinical safety and regulatory studies
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
The accelerated approval is supported by results from part 1 of the ESSENCE trial
Subscribe To Our Newsletter & Stay Updated